Physician profile
Michael D Johnston
NPI 1417160771
$6,787.30
in general payments reported to CMS, 2019-2025
11 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $600 · 2021: $651 · 2022: $126 · 2023: $1,003 · 2024: $2,468 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,504 · Travel and Lodging: $2,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.89 |
| Travel and Lodging | $2,248.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,860.93 | 2019-2025 | Aveir, Assurity, Jot Dx |
| Janssen Pharmaceuticals, INC | $1,181.99 | 2019-2024 | Xarelto |
| Amgen INC. | $126.57 | 2024-2025 | Repatha, Repatha |
| Intuitive Surgical, INC. | $126.21 | 2025 | |
| Abiomed | $109.12 | 2023 | Impella |
| Acell, INC. | $97.42 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $87.80 | 2021-2023 | Farxiga |
| Edwards Lifesciences Corporation | $71.31 | 2024 | Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.63 | 2019 | |
| Merck Sharp & Dohme LLC | $38.31 | 2022 | |
| Medtronic, INC. | $18.01 | 2024 | Azure Xt Dr Mri Surescan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.